Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was incorporated in 2015 and is based in South San Francisco, California.
IPO Year: 2020
Exchange: NASDAQ
Website: nkartatx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/9/2024 | $14.00 | Buy | Rodman & Renshaw |
| 8/14/2024 | $16.00 | Outperform → Strong Buy | Raymond James |
| 3/22/2024 | $13.00 → $16.00 | Strong Buy → Outperform | Raymond James |
| 12/22/2022 | Outperform → Perform | Oppenheimer | |
| 10/10/2022 | $25.00 | Buy | Canaccord Genuity |
| 7/28/2022 | $26.00 | Buy | Needham |
| 7/18/2022 | $30.00 | Outperform | SVB Leerink |
| 3/11/2022 | $17.00 | Outperform | Raymond James |
| 3/8/2022 | $25.00 | Buy | HC Wainwright & Co. |
| 1/6/2022 | Outperform | William Blair |
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)
4 - Nkarta, Inc. (0001787400) (Issuer)
SC 13G - Nkarta, Inc. (0001787400) (Subject)
SC 13G/A - Nkarta, Inc. (0001787400) (Subject)
SC 13G/A - Nkarta, Inc. (0001787400) (Subject)
SC 13G/A - Nkarta, Inc. (0001787400) (Subject)
SC 13G/A - Nkarta, Inc. (0001787400) (Subject)
SC 13G/A - Nkarta, Inc. (0001787400) (Subject)
SC 13D/A - Nkarta, Inc. (0001787400) (Subject)
SC 13D/A - Nkarta, Inc. (0001787400) (Subject)
SC 13D/A - Nkarta, Inc. (0001787400) (Subject)
SC 13D/A - Nkarta, Inc. (0001787400) (Subject)
Rodman & Renshaw initiated coverage of Nkarta with a rating of Buy and set a new price target of $14.00
Raymond James upgraded Nkarta from Outperform to Strong Buy and set a new price target of $16.00
Raymond James downgraded Nkarta from Strong Buy to Outperform and set a new price target of $16.00 from $13.00 previously
Oppenheimer downgraded Nkarta from Outperform to Perform
Canaccord Genuity initiated coverage of Nkarta with a rating of Buy and set a new price target of $25.00
Needham initiated coverage of Nkarta with a rating of Buy and set a new price target of $26.00
SVB Leerink initiated coverage of Nkarta with a rating of Outperform and set a new price target of $30.00
Raymond James initiated coverage of Nkarta with a rating of Outperform and set a new price target of $17.00
HC Wainwright & Co. initiated coverage of Nkarta with a rating of Buy and set a new price target of $25.00
William Blair initiated coverage of Nkarta with a rating of Outperform
New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, could modify refractory autoimmune disease while maintaining NK-driven safety profile Off-the-shelf accessibility and proprietary engineering could eliminate burdens of autologous products and may enable differentiating conditioning regimen Resource prioritization and cost reductions expected to extend cash runway by one year into 2026 to support important clinical data readouts in 2024 Estimated cash and cash equivalents of $278.4 mil
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m. ET to discuss clinical program updates and organizational cost measures and resource prioritization to support clinical milestones. Conference Call and WebcastTo access the conference call, please register through this link: https://nkarta-business-update.open-exchange.net/registration A replay will be archived on the Investors section of Nkarta's website, www.nkartatx.com, for approximately four weeks. About NkartaNkart
Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating Ara-C (cytarabine)In patients with r/r AML treated with a three-dose regimen of NKX101 at 1.5 billion cells per dose after fludarabine/Ara-C for lymphodepletion, n=6 4 of 6 patients achieved complete response (67% CR/CRi, 50% CR rate)2 CRs with MRD negativity1 patient deepened response to MRD negative CRi with additional cycles NKX101 was well tolerated across dose-levels and lymphodepletion regimensExpansion cohort incorporating Ara-C based lymphodepletion expected to be the basis of NKX101 development moving forwardUpdated clinic
SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, June 27, 2023 at 8:00 a.m. ET to review updated clinical data from the ongoing clinical trial of NKX101, its allogeneic, off-the-shelf CAR NK cell therapy candidate engineered to target NKG2D ligands on cancer cells. Conference Call and WebcastTo access the conference call, please register through this link: https://nkx101-clinical-update-conference-call.open-exchange.net/registration Accompanying slides will also be available on the Investors section
7 of 10 patients treated with NKX019 monotherapy at 1 billion and 1.5 billion CAR NK cells per dose achieved complete response (70% CR rate)5 CRs achieved across all dose levels after a single cycle (3 weekly doses) of NKX019 monotherapy; 3 partial responses deepened to CR with additional cyclesPatients with CR observed across multiple NHL histologies, including LBCLConsolidation dosing administered to 7 patients with CRs with aim to eradicate residual tumor cells and prolong responseDurable responses of greater than 6 months achieved in multiple patientsEarly safety profile supports outpatient administration and shows no neurotoxicity / ICANS, graft versus host disease (GvHD), or >Gr3 cytok
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will host a conference call on Monday, December 5, 2022 at 8:00 a.m. ET to review updated clinical data from the ongoing clinical trial of NKX019, its CD19-directed CAR NK cell therapy candidate. Conference Call and WebcastTo access the conference call, please register through this link:https://nkarta-nkx019-clinical-update-conference-call.open-exchange.net/registration Accompanying slides will be available on the Investors section of Nkarta's website, www.nkartatx.com, and
NKX101 – 3 of 5 patients with relapsed / refractory AML treated with a three-dose regimen consisting of 1B or 1.5B CAR NK cells per dose achieved complete response with full hematologic recovery (60% CR rate); 2 of 3 CRs are MRD negative NKX019 – 5 of 6 patients with relapsed / refractory NHL treated with a three-dose regimen consisting of 1B CAR NK cells per dose achieved response (83% ORR) and 3 of 6 achieved complete response (50% CR rate); responses included DLBCL No cytokine release syndrome (CRS), neurotoxicity or graft versus host disease (GvHD) reported for either program Higher dose regimen of 1.5 billion x 3 doses of CAR NK cells is being evaluated in both programs Updated dat
Call scheduled for Monday, April 25, 2022 8:00 a.m. ET Clinical trial investigators to participate SOUTH SAN FRANCISCO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will host a conference call on Monday, April 25, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 1 clinical trials assessing two lead clinical programs, NKX101 and NKX019. Leading investigators from the two clinical trials will join management for the discussion. Conference Call and Webcast To access the conference call, please dial: +1 (866) 518-6930 (d
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 24th Annual Needham Virtual Healthcare ConferenceApril 8, 202511:00 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmu
Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune indications expected in second half of 2025Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestonesCash balance of $380.5 million on December 31, 2024, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWI
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences: TD Cowen 45th Annual Health Care ConferenceMarch 3, 20253:10 p.m. ET – fireside chat Leerink Partners 2025 Global Healthcare ConferenceMarch 10, 20253:00 p.m. ET – fireside chat A simultaneous webcast of the events will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the
Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial (IST) expands the development of NKX019 to neuromuscular autoimmune disease myasthenia gravis Patient dosing initiated and enrollment open in Ntrust-1 and IST of NKX019 in systemic lupus erythematosus Clinical data from Ntrust-1 and Ntrust-2 planned for 2025 SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the opening of Ntrust-2 to enrollment and the IND clearance for an investigator-spon
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: 7th Annual Evercore HealthCONx ConferenceDecember 4, 20242:10 p.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its c
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: Stifel 2024 Healthcare ConferenceNovember 19, 202410:55 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies. By combining its cell ex
First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studiesEnrollment in Ntrust-2 expected to initiate by year-end 2024 Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025No further NKX019 development in lymphoma planned Platform prioritized to focus on advancement of NKX019 for multiple autoimmune diseases Cash balance of $405.3 million on September 30, 2024, including cash, cash equivalents and investments, expected to fund operations into late 2027 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical compa
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 10, 202412:30 p.m. ET – fireside chat A simultaneous webcast of each event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies
Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitisPreliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025Cash balance of $426.7 million on June 30, 2024, including cash, cash equivalents and investments, expected to fund operations into late 2027 SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2024. "Patients remain our fo
SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that researchers at Columbia University Irving Medical Center (CUIMC) have initiated an investigator-sponsored trial ("IST") of NKX019, Nkarta's allogeneic, CD19-directed chimeric antigen receptor (CAR) NK-cell therapy in patients with systemic lupus erythematosus (SLE). The IST broadens the clinical evaluation of NKX019 in lupus. In June 2024, Nkarta announced the initiation of Ntrust-1, its Phase 1 clinical trial of NKX019 in patients with lupus nephritis (LN). The single-center, single-arm,
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings. "This new leadership structure enables Nkarta to meet this transformative moment for cell therapy as
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimenNKX019 clinical data presented at EHA 2023 and ICML 2023 meetingsClinical updates planned for NKX019 in the second half of 2023 and NKX101 in the first half of 2024Cash and cash equivalents of $302.2 million on June 30, 2023; cash runway anticipated to fund operations into 2025 SOUTH SAN FRANCISCO, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2
SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the appointment of Alyssa Levin as Chief Financial and Business Officer. "Alyssa is a results-oriented leader with substantial financial and transaction experience, a proven track record of driving business transformation, and strong drug development knowledge that will be essential as we continue to advance our pipeline of groundbreaking NK cell therapies," said Paul J. Hastings, President and CEO of Nkarta. "We are excited to have Alyssa join our leadership team and look forward to
Oxford Biomedica Appoints Leone Patterson as Non-Executive Director Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director. Ms Patterson shall join the Board on 1st May 2023. Ms Patterson has more than 20 years of public company biotech experience including in the cell and gene therapy industry and has managed significant growth within international commercial companies working across areas including strategy, finance, operations and governance. She is currently the Chief Financial and Business Officer a
SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the appointment of David R. Shook, MD, as Vice President, Clinical Development. Dr. Shook is a practicing pediatric hematologist, oncologist, and transplanter, and an early pioneer of natural killer (NK) cell therapy. He currently directs Nkarta's co-lead clinical programs, NKX101 and NKX019. In his expanded role, Dr. Shook will lead all clinical development and regulatory activities at Nkarta. Kanya Rajangam, MD, PhD, has resigned as Chief Medical Officer, effective Jun
Appointment brings extensive operational expertise in supply chain and novel commercial-scale manufacturing systems SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, announced today the appointment of Angela M. Thedinga, MBA, MPH, to its Board of Directors. "The speed of manufacturing innovation in cell and gene therapies in recent years has accelerated significantly. Angela is one of a handful of people who have been at the center of this activity," said Paul J. Hastings, President and CEO of Nkarta. "Her expertise and insight in
DEFA14A - Nkarta, Inc. (0001787400) (Filer)
DEF 14A - Nkarta, Inc. (0001787400) (Filer)
10-K - Nkarta, Inc. (0001787400) (Filer)
8-K - Nkarta, Inc. (0001787400) (Filer)
SCHEDULE 13D/A - Nkarta, Inc. (0001787400) (Subject)
SCHEDULE 13G/A - Nkarta, Inc. (0001787400) (Subject)
SCHEDULE 13G - Nkarta, Inc. (0001787400) (Subject)
S-8 - Nkarta, Inc. (0001787400) (Filer)
10-Q - Nkarta, Inc. (0001787400) (Filer)
8-K - Nkarta, Inc. (0001787400) (Filer)